Help HCA ask for Federal Funding for Treatment and Prevention of HSV!

The landscape for Herpes treatment and prevention is, while the are glimmers of hope, very ugly. There are no public health interventions to stop transmission and no accurate test to diagnose asymptomatic infection. The treatment pipeline is slim, improving – yet slim. And NIH is investing less than 10 million a year in clinical researchContinue reading “Help HCA ask for Federal Funding for Treatment and Prevention of HSV!”

Hope for Herpes Keratitis Cure in China: Study results expected in 2022

In the global race for a Herpes cure, China is taking the lead. For the first time, transient gene-editing of the herpes simplex virus type 1 (HSV-1) using mRNA-based CRISPR was shown to cure herpes keratitis in mice. Chinese researchers reported in a paper published January 11, 2021 of Nature Biotechnology. In a paper publishedContinue reading “Hope for Herpes Keratitis Cure in China: Study results expected in 2022”

National Strategy for Herpes: A DHHS Strategic Plan in House FY 2022 Budget

Herpes Cure Advocacy confirms a national strategy and strategic plan for Herpes Simplex Virus Types 1 and 2 in the approved House FY 2022 budget. On page 245, the House FY budget report reads: National Strategy for Herpes Simplex Virus (HSV), Types 1 and 2.—The Committee recognizes that an estimated 1 in 3 Americans hasContinue reading “National Strategy for Herpes: A DHHS Strategic Plan in House FY 2022 Budget”

Herpes Cure Research at Sanofi

Sanofi is the largest company devoted entirely to vaccines and is currently running a Phase I/II clinical trial on 6 different formulations of HSV529, G103, and an adjuvant. HSV529 is a replication-defective vaccine while G103 is a subunit vaccine. In a Phase I trial completed in 2018, HSV529 induced a statistically significant increase in antibodyContinue reading “Herpes Cure Research at Sanofi”